CVSI CV Sciences, Inc.

OTC
$0.01

CV Sciences Scrapes to Breakeven on Margin Gains and a Legal Windfall, but a December Hemp Cliff and Dilution Overshadow the Progress

CV Sciences (CVSI) reported breakeven earnings of $0.00 per share for the September quarter on revenue of $3.03 million, down 7.0% from a year earlier. There was no consensus estimate or Earnings Whisper to measure against, so the question is whether the business is actually improving. On profitability, it is. Gross margin reached 50.0%, operating expenses fell again, and adjusted EBITDA turned positive at $32,000 after losses of $118,000 a year ago and $132,000 last quarter. The top line, however, is still shrinking year over year, and federal restrictions on hemp-derived cannabinoids take effect on December 11. That is the central tension: management has shown it can run the company near breakeven at about $3 million a quarter, just as the regulatory ground under its core category is about to shift.

The quality of the quarter deserves scrutiny. Reported operating income of $377,000 includes a $500,000 gain from settling a legal action against Procopio, the company's former counsel. Without that gain, the company still posted an operating loss. That loss was smaller than the $275,000 loss a year ago, which supports management's claim that results improved even excluding the settlement. Below the operating line, $470,000 of convertible-note charges pushed the GAAP result to a $93,000 net loss: $263,000 from losses on debt conversions and $207,000 from changes in the notes' fair value. The non-GAAP figure, net income of $9,000, depends on removing both the settlement gain and those financing costs.

The financing costs matter beyond the income statement. Weighted shares rose to 226 million from 184 million a year ago, and 235.7 million shares were outstanding at quarter end. On the call, the CEO acknowledged that the convertible noteholder's selling of converted shares is weighing on the stock.

The call did show some genuine operating improvement:

  • Revenue rose 1.4% sequentially, the first quarter-over-quarter gain this year after declines of 3% in Q1 and 7% in Q2.
  • Gross margin recovered from 48.6% in Q2 and 48.9% in Q1, helped by contract manufacturing revenue, product cost reductions and mix.
  • Operating expenses fell to $1.6 million from $1.7 million in Q2 and $1.9 million in Q1.
  • Operating cash flow was $64,000 in Q3 and roughly $184,000 year to date.
  • Management's tone was its most upbeat of the year. It now says cash breakeven has been "effectively achieved," after describing the company as "approaching" breakeven on prior calls.

The unit data conflict. The release says total units fell 4.7% year over year, alongside lower average selling prices. The call cited a 4% unit increase driven by new retail placement of non-cannabinoid +PlusHLTH products. Neither source reconciles the two, and they likely use different baselines. Either way, falling prices are offsetting whatever volume gains the company is getting.

The forward-looking picture is mixed:

  • **New initiatives:** The company launched plushealth.com as a dedicated non-cannabinoid storefront. It also flagged a new proprietary broad-spectrum CBD oil designed to meet the strictest potential regulatory standards, with more detail promised within 30 days. That product may be the most important near-term development given the December deadline.
  • **Slower diversification:** The non-cannabinoid launch cadence slipped from "throughout 2026" to "the next 12 to 24 months."
  • **Missing growth stories:** The CMS hemp healthcare-benefit channel and pet momentum through Chewy, both highlighted earlier in the year, went unmentioned.
  • **Channel mix:** Direct-to-consumer share of revenue edged down to 45.6% from 46.2%.
  • **Guidance and scrutiny:** Management gave no formal guidance, and no analysts asked questions.
  • **New-product contribution:** Products launched since January 2023 made up 48% of revenue, which shows the innovation pipeline matters. It also shows that much of the established hemp franchise is eroding.

The balance sheet improved, but only modestly. Working capital rose to $0.7 million from $0.1 million at year end, helped by the settlement and by converting debt to equity. Cash is still only $308,000, against $2.45 million of accrued expenses and $741,000 of convertible notes carried at fair value. If December's regulatory change disrupts cannabinoid sales, the company has very little cushion.

Market context is thin. No sentiment reading or current price was available. Shares opened at $0.03 after the prior report, and the 200-day moving average also sits at $0.03, suggesting a stock that has drifted sideways at a sub-nickel level. Ongoing conversion selling by the noteholder caps upside regardless of operating progress.

The bottom line is that CV Sciences delivered its cleanest operating quarter of the year: higher margins, lower costs, positive adjusted EBITDA and cash-flow breakeven. Yet the headline breakeven leans on a one-time legal gain, sales remain below last year, and shareholders are absorbing heavy dilution from convertible notes. The next few months hinge on two things the company has not yet clarified: how the December 11 hemp redefinition affects sales, and whether the new compliant CBD oil and the slower +PlusHLTH rollout can make up for it.

← Back to CVSI news